While the biotech world chases the next mRNA breakthrough, Osivax is quietly building a different kind of immune arsenal. This French biotech isn't just making another vaccine—it's engineering a platform that activates both arms of the immune system for universal protection. With $45.4M in funding and a team of 71, they're playing a long game that most VCs would consider too risky.

"They're not building a vaccine for a virus—they're building a platform for viral defense. That's the difference between incremental and revolutionary."

The leadership team reveals the company's clinical focus. With Delphine Guyon-Gellin as Chief Business Development Officer and COO, Cécile Lacroix leading Clinical QA, and Jessika Tourneur directing Clinical Development, the emphasis is squarely on execution. These aren't academic researchers—they're operators building a pipeline. The absence of a CTO or Chief Scientific Officer in the listed key people suggests business development and clinical execution are the current priorities, likely because they've already validated the core science.

• Universal vaccine platform targeting entire viral families, not single strains
• Dual immune system activation: both antibody and T-cell responses
• Pre-commercial stage with $11M in revenue (likely partnerships or grants)
• European base with global ambitions (French leadership team)
• Lean digital presence signals focus on R&D over marketing
• Strong institutional backing with $45.4M in total funding